Search Results for "Tingkatan Satu Sejarah Nota"

04:27 EDT 4th July 2015 | BioPortfolio

Matching Channels

None

Matching News

The devil's helmet for a legendary tiger moth

(Pensoft Publishers) The Menetries' tiger moth (Borearctia menetriesii) is the most rare and enigmatic representative among the Palearctic Arctiinae. During an expedition in almost inaccessible wild t...

ValiRx makes milestone payment as lead compound progresses

Drug developer ValiRx (LON:VAL) has paid £80,000 to Cancer Research Technology after lead drug VAL201 passed first patient dosing in its ongoing phase/II trial. CRT took the milestone payment in...

ValiRx: Bioscience Innovation

In this interview, filmed during BioEurope 2008 in Madrid, Fintan Walton speaks with Satu Vainikka, CEO of ValiRx, an AIM listed biopharmaceutical company based in the UK. Focusing on epigenetics, Val...

VailRx raises another £800,000 to fund clinical work

Cancer drug developer ValiRx (LON:VAL) has raised a further £800,000 through a placing to help fund its two lead products to and through clinical trials. The placing, at 0.2p, follows a similar-...

ValiRx shares rocket on VAL401 US patent approval

Shares in ValiRx (LON:VAL) shot up almost 24% as it said its ValiSeek joint venture with Tangent Reprofiling had received notice that a US patent covering the composition of its cancer treatment VAL40...

ValiRx picks up first contract for gene technology platform

ValiRx (LON:VAL) has picked up its first contract for TRAC, the gene expression and biomarker tracking technology it acquired in February. Admescope, a US bio-analytical specialist, will use the techn...

ValiRx encouraged by efficacy signs in cancer compound trial

Drug developer ValiRx (LON:VAL) has noted evidence of potential efficacy in the phase I/II trial of its lead cancer treatment. VAL201 is being trialled on patients with advanced or metastatic prosta...

ValiRx joint-venture making progress

Life sciences firm ValiRx (LON:VAL) said its ValiSeek joint venture with Tangent Reprofiling has begun the process of taking its drug candidate for cancer into full-blown clinical trials. Regulatory p...

Matching PubMed Articles

A 67/68Ga-labeling agent that liberates 67/68Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels.

The renal localization of gallium-67 or gallium-68 (67/68Ga)-labeled low molecular weight (LMW) probes such as peptides and antibody fragments constitutes a problem in targeted imaging. Wu et al. prev...

PET of Follicle-Stimulating Hormone Receptor: Broad Applicability to Cancer Imaging.

Follicle-stimulating hormone receptor (FSHR) is selectively overexpressed by the vascular endothelium in a wide variety of tumors and confirmed to play critical roles in angiogenesis, tumor invasion, ...

(68)Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake.

Nanogels from Metal-Chelating Crosslinkers as Versatile Platforms Applied to Copper-64 PET Imaging of Tumors and Metastases.

Metals are essential in medicine for both therapy and diagnosis. We recently created the first metal-chelating nanogel imaging agent, which employed versatile, reproducible chemistry that maximizes ch...

Tunable Rare Earth fcu-MOF Platform: Access to Adsorption Kinetics Driven Gas/Vapor Separations via Pore Size Contraction.

Reticular chemistry approach was successfully employed to deliberately construct new rare-earth (RE, i.e. Eu3+, Tb3+ and Y3+) fcu metal‒organic frameworks (MOFs) with restricted window apertures. Co...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement